The Role of EZH2 Inhibitor, GSK-126, in Seizure Susceptibility


GSK-126 is recognized as an inhibitor of enhancer of zeste homolog-2 (EZH2) activity. Because of its inhibition of EZH2 activation, GSK-126 is considered a potential anti-tumor drug. EZH2 is a histone methyltransferase that catalyzes histone 3 tri-methylation at lysine 27 (H3K27me3), resulting in gene silencing. A previous report showed that decreased H3K27me3 levels in the hippocampus may promote seizure susceptibility, possibly restricting the clinical application of GSK-126. The role of GSK-126 in seizure susceptibility was investigated in this study. We first determined a critical concentration of pentamethazol (PTZ) under which mice exhibit no seizures. We then found that mice pretreated with GSK-126 and injected with the same concentration of PTZ experienced marked convulsions. Peripheral injections of GSK-126 decreased H3K27me3 levels in the hippocampus of mice, while some seizure-related genes (Oasl1, Sox7, armcx5, Ncx3, etc.) were found to be differentially expressed in the hippocampus of those mice . These differences in the expression levels might reflect the crucial role of these genes and related pathways in the promotion of seizure susceptibility. Our results suggest that GSK-126 promotes seizure susceptibility due to its role as an EZH2 inhibitor. These findings may provide evidence to support the development of GSK-126 as a clinical drug.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Data Availability

We declared that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality.


  1. Akizu N, Estaras C, Guerrero L, Marti E, Martinez-Balbas MA (2010) H3K27me3 regulates BMP activity in developing spinal cord. Development (Cambridge, England) 137:2915–2925.

    CAS  Article  Google Scholar 

  2. Chen YT, Zhu F, Lin WR, Ying RB, Yang YP, Zeng LH (2016) The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. Cancer Chemother Pharmacol 77:757–765.

    CAS  Article  PubMed  Google Scholar 

  3. Dhir A (2012) Pentylenetetrazol (PTZ) kindling model of epilepsy. Curr Protoc Neurosci Chapter 9:Unit9.37.

    Article  PubMed  Google Scholar 

  4. Fioravanti R, Stazi G, Zwergel C, Valente S, Mai A (2018) Six years (2012-2018) of researches on catalytic EZH2 inhibitors: the boom of the 2-pyridone compounds. Chem Rec (New York, NY) 18:1818–1832.

    CAS  Article  Google Scholar 

  5. Gürol G, Demiralp DÖ, Yılmaz AK, Akman Ö, Ateş N, Karson A (2015) Comparative proteomic approach in rat model of absence epilepsy. J Mol Neurosci 55:632–643.

    CAS  Article  PubMed  Google Scholar 

  6. Henriquez B, Bustos FJ, Aguilar R, Becerra A, Simon F, Montecino M, van Zundert B (2013) Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons. Mol Cell Neurosci 57:130–143.

    CAS  Article  PubMed  Google Scholar 

  7. Kang TC, An SJ, Park SK, Hwang IK, Suh JG, Oh YS, Bae JC, Won MH (2002) Alterations in Na+/H+ exchanger and Na+/HCO3- cotransporter immunoreactivities within the gerbil hippocampus following seizure. Brain Res Mol Brain Res 109:226–232.

    CAS  Article  PubMed  Google Scholar 

  8. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100:11606–11611.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Li X, Giri V, Cui Y, Yin M, Xian Z, Li J (2019) LncRNA FTX inhibits hippocampal neuron apoptosis by regulating miR-21-5p/SOX7 axis in a rat model of temporal lobe epilepsy. Biochem Biophys Res Commun 512:79–86.

    CAS  Article  PubMed  Google Scholar 

  10. Liu H, Peng L, So J, Tsang KH, Chong CH, Mak PHS, Chan KM, Chan SY (2018) TSPYL2 regulates the expression of EZH2 target genes in neurons. Mol Neurobiol 56:2640–2652.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. McCabe MT et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108–112.

    CAS  Article  PubMed  Google Scholar 

  12. Momparler RL, Cote S, Momparler LF, Idaghdour Y (2017) Inhibition of DNA and histone methylation by 5-aza-2’-deoxycytidine (decitabine) and 3-deazaneplanocin-A on antineoplastic action and gene expression in myeloid leukemic cells. Front Oncol 7:19.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II Motor seizure. Electroencephalogr Clin Neurophysiol 32:281–294

    CAS  Article  Google Scholar 

  14. Rassner MP, Moser A, Follo M, Joseph K, van Velthoven-Wurster V, Feuerstein TJ (2016) Neocortical GABA release at high intracellular sodium and low extracellular calcium: an anti-seizure mechanism. J Neurochem 137:177–189.

    CAS  Article  PubMed  Google Scholar 

  15. Schubert HL, Blumenthal RM, Cheng X (2003) Many paths to methyltransfer: a chronicle of convergence. Trends Biochem Sci 28:329–335.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Sun D, Ma H, Ma J, Wang J, Deng X, Hu C, Deng X (2018) Canonical transient receptor potential channel 3 contributes to febrile seizure inducing neuronal cell death and neuroinflammation. Cell Mol Neurobiol 38:1215–1226.

    CAS  Article  PubMed  Google Scholar 

  17. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, Rubin MA, Chinnaiyan AM (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629.

    CAS  Article  PubMed  Google Scholar 

  18. Varambally S et al (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (New York, NY) 322:1695–1699.

    CAS  Article  Google Scholar 

  19. Vezzani A, French J, Bartfai T, Baram TZ (2011) The role of inflammation in epilepsy. Nat Rev Neurol 7:31–40.

    CAS  Article  PubMed  Google Scholar 

  20. Wang Z, Fan Y, Xu J, Li L, Heng D, Han S, Yin J, Peng B, Liu W, He X (2014) Transcriptome analysis of the hippocampus in novel rat model of febrile seizures. PLoS One 9:e95237.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. Wang Z, Zhang Y, Fang J, Yu F, Heng D, Fan Y, Xu J, Peng B, Liu W, Han S, He X (2017) Decreased methylation level of H3K27me3 increases seizure susceptibility. Mol Neurobiol 54:7343–7352.

    CAS  Article  PubMed  Google Scholar 

  22. Yadav R, Weng HR (2017) EZH2 regulates spinal neuroinflammation in rats with neuropathic pain. Neuroscience 349:106–117.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. Zeng D, Liu M, Pan J (2017) Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. Oncotarget 8:3396–3411.

    Article  PubMed  Google Scholar 

  24. Zhang P, de Gooijer MC, Buil LC, Beijnen JH, Li G, van Tellingen O (2015) ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors. Int J Cancer 137:2007–2018.

    CAS  Article  PubMed  Google Scholar 

  25. Zhou J, Goldberg EM, Leu NA, Zhou L, Coulter DA, Wang PJ (2014) Respiratory failure, cleft palate and epilepsy in the mouse model of human Xq22.1 deletion syndrome. Hum Mol Genet 23:3823–3829.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references


This work was financially supported by the National Natural Sciences Foundation of China (grant numbers 81801168, 81802063); the Natural Sciences Foundation of Jiangsu Province (grant number BK20160228); the Natural Science Foundation of the Jiangsu Higher Education Institutions (grant number 18KJB320026); and the Starting Foundation for Talents of Xuzhou Medical University (grant number D2017022).

Author information




ZW and TL conceived and designed the original study. ZW and YS conducted the statistical analysis and drafted the manuscript. YS and DZ contributed to the acquisition and interpretation of data. ZW and TL participated in critical revision of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Zhongcheng Wang or Ting Lan.

Ethics declarations

Competing Interests

The authors declare that they have no competing interests.

Ethics Approval

All animal procedures were approved by the Committee on the Ethics of Animal Experiments of the Xuzhou Medical University (China).

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Supplement Fig. 1

The Vocalno Plot of different expressed genes. Vocalno Plot indicated up-regulated and down-regulated genes between the GSK-126 and control groups. Up-regulated and down-regulated genes were colored in red and blue, respectively. (PNG 248 kb)

High Resolution Image (TIF 1353 kb)


(DOCX 17 kb)


(DOCX 16 kb)


(DOCX 33 kb)


(DOC 31 kb)


(XLSX 148 kb)


(XLSX 83 kb)


(XLSX 45 kb)


(MP4 19559 kb)

ESM 10

(MP4 21000 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, Z., Su, Y., Zhuang, D. et al. The Role of EZH2 Inhibitor, GSK-126, in Seizure Susceptibility. J Mol Neurosci 71, 556–564 (2021).

Download citation


  • GSK-126
  • EZH2
  • H3K27me3
  • Seizure